Specifically, CBD (Philpott et al., 2017), CB1 agonists (Schuelert and McDougall, 2008), CB2 agonists (Yao et al., 2008; Schuelert et al., 2010), as well as FAAH inhibitors (Ahn et al., 2011; McDougall et al., 2017), have been shown to reduce pain, allodynia, or nociceptive fiber firing in animal models of osteoarthritis. This evidence concerns the gene OPN1MW and osteoarthritis.